Related Experiment Videos
[The diagnostic utility of PSA density]
J Alcover1, J Filella, J R Vendrell
1Servicio y Cátedra de Urología, Hospital Clinic i Provincial, Facultad de Medicina, Universidad de Barcelona.
Actas Urologicas Espanolas
|March 1, 1995
Summary
Prostate-Specific Antigen (PSA) density improves prostate cancer diagnosis sensitivity. A 0.15 cut-off correctly identified most benign cases but showed lower specificity, suggesting its utility for mild cancer suspicion.
Area of Science:
- Urology
- Oncology
- Medical Diagnostics
Background:
- Serum PSA levels are crucial for prostate cancer detection but can be limited by benign conditions.
- Prostate-Specific Antigen (PSA) density is a newer metric aimed at enhancing diagnostic accuracy.
- Benign Prostate Hyperplasia (BHP) can elevate PSA, complicating cancer diagnosis.
Purpose of the Study:
- To evaluate the diagnostic utility of PSA density in differentiating prostate cancer from BHP.
- To determine the sensitivity and specificity of PSA density using a specific cut-off value.
Main Methods:
- Assessed PSA density in 47 patients with BHP and 26 with prostate adenocarcinoma.
- Utilized a cut-off value of 0.15 for PSA density analysis.
- Analyzed sensitivity and specificity, considering patient subgroups and complications.
Main Results:
- A PSA density cut-off of 0.15 correctly identified 97% of uncomplicated BHP cases.
- Overall sensitivity for detecting prostate cancer was 73%, reaching 100% in Stage C.
- Specificity was lower (41% false positives) in complicated BHP cases (urinary infection, catheter use).
Conclusions:
- PSA density demonstrates significant utility in diagnosing prostate cancer, particularly in cases with mild suspicion.
- The test is highly effective in ruling out benign conditions but requires careful interpretation in patients with complicating factors.
- Further research may refine PSA density's role in clinical decision-making for prostate cancer screening.